Route: GAVAGE

Test Type: 26-39 WEEKS

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

. NOTE

Lab: NCTR

C Number: C20310B

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

**Lock Date:** 04/20/2010

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Female

**TDMSE Version:** 2.2.0

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Disposition Summary						
Animals Initially In Study	25	25	25	25	24	25
Early Deaths						
Moribund Sacrifice		1		1	2	1
Natural Death				1	1	
Survivors						
Moribund Sacrifice		2	3	1	2	1
Natural Death		2	2	2		1
Terminal Sacrifice	25	20	20	20	19	22
Animals Examined Microscopically	25	25	25	25	24	25
ALIMENTARY SYSTEM						
Gallbladder	(25)	(23)	(23)	(22)	(23)	(23)
Intestine Large, Cecum	(25)	(23)	(23)	(22)	(23)	(24)
Hyperplasia, Lymphoid			1 [1.0]			
Intestine Small, Duodenum	(25)	(23)	(23)	(22)	(23)	(24)
Intestine Small, Ileum	(25)	(23)	(23)	(22)	(23)	(24)
Liver	(25)	(25)	(23)	(24)	(23)	(25)
Basophilic Focus		1				
Clear Cell Focus			1			
Hematopoietic Cell Proliferation		1 [1.0]		1 [2.0]		
Hepatodiaphragmatic Nodule			1			
Infiltration Cellular, Lymphocyte	1 [1.0]	3 [1.3]	2 [1.0]	6 [1.3]	3 [1.7]	2 [1.0]
Inflammation, Chronic Active	1 [1.0]	2 [1.0]	1 [1.0]	2 [1.0]	2 [1.0]	1 [1.0]
Necrosis						1 [4.0]
Tension Lipidosis	2 [1.0]		2 [1.0]	3 [1.7]	2 [1.5]	
Vacuolization Cytoplasmic	14 [1.1]	13 [1.4]	14 [1.3]	11 [1.5]	13 [1.8]	17 [1.2]
Centrilobular, Degeneration				1 [2.0]		
Mesentery	(0)	(1)	(0)	(0)	(0)	(0)
Fat, Necrosis						
Pancreas	(25)	(25)	(25)	(22)	(23)	(25)
Infiltration Cellular, Lymphocyte	2 [1.0]	4 [1.0]	2 [1.0]	1 [1.0]	3 [1.0]	3 [1.3]
Necrosis	1 [4.0]					
Salivary Glands	(25)	(25)	(25)	(24)	(23)	(25)

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Infiltration Cellular, Lymphocyte	22 [1.4]	17 [1.5]	18 [1.2]	19 [1.6]	16 [1.3]	18 [1.5]
Stomach, Forestomach	(25)	(24)	(24)	(24)	(23)	(25)
Inflammation, Suppurative		1 [2.0]				
Inflammation, Chronic Active					1 [2.0]	
Ulcer	1 [2.0]	1 [2.0]			1 [2.0]	
Epithelium, Hyperplasia	2 [2.0]	1 [2.0]			1 [3.0]	
Stomach, Glandular	(25)	(23)	(23)	(22)	(23)	(25)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(25)	(25)	(25)	(25)	(23)	(25)
Heart	(25)	(25)	(25)	(25)	(24)	(25)
Inflammation, Chronic Active			1 [1.0]			
Mineralization			1 [2.0]	1 [1.0]		
ENDOCRINE SYSTEM						
Adrenal Cortex	(25)	(24)	(24)	(25)	(23)	(25)
Accessory Adrenal Cortical Nodule	1			1		
Hypertrophy	1 [3.0]					
Infiltration Cellular, Polymorphonuclear						
Vacuolization Cytoplasmic	16 [1.9]	14 [1.4]	16 [1.6]	16 [1.4]	13 [1.6]	15 [1.3]
Subcapsular, Hyperplasia	25 [1.5]	24 [1.4]	24 [1.3]	24 [1.2]	22 [1.5]	24 [1.3]
Islets, Pancreatic	(25)	(24)	(25)	(25)	(23)	(25)
Hyperplasia		2 [1.0]		1 [1.0]		1 [1.0]
Parathyroid Gland	(20)	(23)	(21)	(20)	(18)	(21)
Cyst						1 [2.0]
Infiltration Cellular, Lymphocyte					1 [1.0]	
Pituitary Gland	(25)	(25)	(24)	(25)	(23)	(24)
Fibrosis			1 [3.0]			
Pars Distalis, Hyperplasia						
Thyroid Gland	(23)	(24)	(25)	(23)	(22)	(25)
Cyst				1 [2.0]		
Ectopic Thymus	3		1		1	1

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(1)	(0)	(0)
GENITAL SYSTEM						
Clitoral Gland	(24)	(24)	(23)	(21)	(21)	(24)
Acinus, Degeneration	9 [2.9]	12 [3.2]	6 [3.0]	5 [3.4]	6 [3.2]	6 [3.2]
Duct, Ectasia Ovary	(25)	(24)	(25)	(24)	(23)	(25)
Atrophy	1 [2.0]	1 [3.0]	1 [3.0]	(24)	(23)	(23)
Cyst	1 [2.0]	3 [2.3]	1 [2.0]	2 [2.0]	3 [2.0]	3 [2.7]
Cyst Dermoid	1 [2.0]	0 [2.0]	1 [3.0]	2 [2.0]	0 [2.0]	0 [2.1]
Hemorrhage			. [0.0]			
Uterus	(25)	(25)	(25)	(23)	(23)	(25)
Atrophy	( - /	( - /	1 [3.0]	( - /	( - /	( - /
Degeneration, Cystic		1 [2.0]				
Endometrium, Hyperplasia, Cystic	22 [1.8]	19 [1.4]	19 [1.8]	19 [2.1]	17 [1.4]	18 [1.4]
Vagina	(25)	(24)	(24)	(24)	(23)	(25)
Infiltration Cellular, Polymorphonuclear		2 [3.0]		2 [3.5]		1 [2.0]
HEMATOPOIETIC SYSTEM						
Bone Marrow	(25)	(24)	(24)	(23)	(23)	(25)
Fibrosis	, ,	, ,	1 [2.0]		, ,	, ,
Hyperplasia	1 [3.0]	2 [2.5]	2 [2.5]	1 [2.0]	3 [3.3]	
Lymph Node	(1)	(3)	(1)	(3)	(4)	(3)
Lumbar, Hyperplasia, Lymphoid						1 [2.0]
Lumbar, Sinus, Dilatation		1 [4.0]				
Pancreatic, Hyperplasia, Lymphoid						1 [4.0]
Renal, Angiectasis		1 [4.0]				
Renal, Hyperplasia, Lymphoid						1 [3.0]
Renal, Thrombus		1 [4.0]				

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Lymph Node, Mandibular	(25)	(25)	(24)	(24)	(23)	(25)
Hyperplasia, Lymphoid	3 [2.3]	, ,	3 [1.7]	4 [1.5]	2 [1.5]	4 [1.8]
Lymph Node, Mesenteric	(25)	(24)	(23)	(24)	(23)	(25)
Angiectasis		1 [2.0]				
Hyperplasia, Lymphoid	1 [1.0]	3 [1.0]	3 [2.0]	4 [2.0]	3 [1.7]	3 [1.7]
Spleen	(25)	(25)	(24)	(24)	(23)	(25)
Hematopoietic Cell Proliferation	2 [2.5]	8 [2.8]	7 [3.1]	6 [2.5]	6 [2.5]	2 [2.5]
Hyperplasia, Lymphoid	20 [2.4]	16 [2.3]	17 [2.4]	14 [2.7]	14 [2.2]	19 [2.5]
Thymus	(25)	(21)	(22)	(22)	(24)	(25)
Atrophy	1 [4.0]		2 [3.5]			
Hyperplasia, Lymphoid	6 [2.2]	2 [2.0]	2 [2.5]	8 [2.0]	6 [2.0]	9 [2.1]
INTEGUMENTARY SYSTEM						
Mammary Gland	(25)	(25)	(25)	(23)	(23)	(25)
Skin	(25)	(25)	(25)	(25)	(23)	(25)
Inflammation, Suppurative		1 [3.0]				
Ulcer		1 [4.0]				
MUSCULOSKELETAL SYSTEM						
Bone	(0)	(0)	(2)	(0)	(0)	(2)
Bone, Femur	(25)	(25)	(25)	(25)	(24)	(25)
Fibro-Osseous Lesion	1 [3.0]	( - /	( - /	( - /	( )	( - /
Skeletal Muscle	(0)	(1)	(2)	(0)	(0)	(0)
Degeneration	<b>、</b> ,	( )	1 [3.0]	( /	( )	( )
NERVOUS SYSTEM						
Brain, Brain Stem	(25)	(24)	(25)	(24)	(23)	(25)
Brain, Cerebellum	(25)	(24)	(25)	(24)	(23)	(25)
Hemorrhage	(==)	1 [1.0]	()	( <del>-</del> ·/	(==)	(==)
Brain, Cerebrum	(25)	(24)	(25)	(24)	(23)	(25)
Mineralization	2 [1.0]	\ <del>-</del> ·/	(==)	3 [1.0]	(==)	1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 26-39 WEEKS

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

Species/Strain. MICE/C3B0F1-+/T1p33(till1Blu)					Lab. NCTK	
C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Peripheral Nerve Axon, Degeneration	(0)	(0)	(1) 1 [4.0]	(0)	(0)	(0)
RESPIRATORY SYSTEM						
Lung Hemorrhage Infiltration Cellular, Lymphocyte	(25)	(24) 1 [2.0]	(24)	(24) 1 [2.0]	(24)	(25) 1 [2.0] 1 [1.0]
Inflammation, Chronic Active		1 [Z.O]			1 [2.0]	1 [1.0]
Metaplasia, Osseous		1 [1.0]				1 [1.0]
Nose	(25)	(25)	(25)	(24)	(24)	(25)
Hyaline Droplet	1 [1.0]	3 [1.3]	4 [1.5]	1 [1.0]	6 [1.8]	4 [1.8]
Trachea	(25)	(24)	(24)	(24)	(23)	(25)
SPECIAL SENSES SYSTEM						
Eye Cataract	(25)	(23)	(23)	(22)	(23)	(24)
Harderian Gland	(25)	(24)	(25)	(25)	(23)	(25)
Infiltration Cellular, Lymphocyte	2 [1.0]				1 [1.0]	1 [1.0]
Inflammation, Chronic Active			1 [4.0]			
URINARY SYSTEM						
Kidney	(25)	(24)	(24)	(24)	(23)	(25)
Casts Protein	14 [1.1]	14 [1.0]	8 [1.0]	10 [1.0]	12 [1.0]	15 [1.1]
Hydronephrosis						
Infarct	1 [2.0]					
Infiltration Cellular, Lymphocyte Metaplasia, Osseous	11 [1.4]	10 [1.2]	11 [1.0]	15 [1.1]	11 [1.3]	13 [1.0]
Mineralization			1 [3.0]			
Renal Tubule, Regeneration			1 [3.0]			
Urinary Bladder	(25)	(24)	(24)	(23)	(23)	(25)
Infiltration Cellular, Lymphocyte	8 [1.1]	4 [1.3]	8 [1.1]	4 [1.0]	8 [1.0]	5 [1.2]

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010

AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

First Dose M/F: NA / 12/22/06

**CAS Number: AZT3TCCOMBO** 

Lab: NCTR

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE

Vehicle

**AZT 60** 

3TC 37.5

**NVP 10.5** 

**AZT 60 3TC 37.5** 

Time Report Requested: 12:30:59

A20,3T12.5,NV3.5

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

opecies/orani: whot/obbot 1 1/11poo(til11bid)			Lab. Notice
C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5	
Disposition Summary			
•			
Animals Initially In Study	24	25	
Early Deaths  Moribund Sacrifice	4		
Natural Death	1 1		
Survivors	ı		
Moribund Sacrifice	1	2	
Natural Death	•	2	
Terminal Sacrifice	21	21	
Animals Examined Microscopically	22	25	
- Animals Examined Microscopically			
ALIMENTARY SYSTEM			
Gallbladder	(21)	(24)	
Intestine Large, Cecum	(21)	(23)	
Hyperplasia, Lymphoid	` ,	,	
Intestine Small, Duodenum	(21)	(24)	
Intestine Small, Ileum	(21)	(23)	
Liver	(22)	(25)	
Basophilic Focus	1		
Clear Cell Focus	1		
Hematopoietic Cell Proliferation			
Hepatodiaphragmatic Nodule			
Infiltration Cellular, Lymphocyte	4 [1.3]	4 [1.3]	
Inflammation, Chronic Active		3 [1.0]	
Necrosis			
Tension Lipidosis	4 [1.8]	3 [2.0]	
Vacuolization Cytoplasmic	13 [1.3]	15 [1.7]	
Centrilobular, Degeneration		3 [2.7]	
Mesentery	(0)	(2)	
Fat, Necrosis		2 [2.5]	
Pancreas	(21)	(24)	
Infiltration Cellular, Lymphocyte	5 [1.0]	2 [2.0]	
Necrosis			
Salivary Glands	(22)	(25)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

**TDMS No.** 20310 - 04

Route: GAVAGE

Test Type: 26-39 WEEKS

Route: GAVAGE

Test Type: 26-39 WEEKS

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59

First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
Infiltration Cellular, Lymphocyte	12 [1.3]	20 [1.4]
Stomach, Forestomach	(21)	(24)
Inflammation, Suppurative	(21)	(21)
Inflammation, Chronic Active		
Ulcer		
Epithelium, Hyperplasia		1 [3.0]
Stomach, Glandular	(21)	(23)
Sistings, Standard	(= · /	(20)
CARDIOVASCULAR SYSTEM		
Blood Vessel	(22)	(25)
Heart	(22)	(25)
Inflammation, Chronic Active		
Mineralization		
ENDOCRINE SYSTEM		
Adrenal Cortex	(22)	(25)
Accessory Adrenal Cortical Nodule	•	•
Hypertrophy		
Infiltration Cellular, Polymorphonuclear		1 [2.0]
Vacuolization Cytoplasmic	16 [1.8]	18 [1.4]
Subcapsular, Hyperplasia	20 [1.6]	24 [1.5]
Islets, Pancreatic	(22)	(25)
Hyperplasia		1 [1.0]
Parathyroid Gland	(21)	(23)
Cyst		
Infiltration Cellular, Lymphocyte		
Pituitary Gland	(22)	(23)
Fibrosis		
Pars Distalis, Hyperplasia		1 [2.0]
Thyroid Gland	(22)	(25)
Cyst	1 [1.0]	
Ectopic Thymus	2	2

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59 First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
GENERAL BODY SYSTEM		
Tissue NOS	(0)	(0)
GENITAL SYSTEM		
Clitoral Gland	(22)	(22)
Acinus, Degeneration	5 [3.4]	11 [2.7]
Duct, Ectasia	- [- ]	1 [3.0]
Ovary	(22)	(25)
Atrophy	1 [2.0]	, ,
Cyst	1 [1.0]	
Cyst Dermoid		
Hemorrhage		1 [2.0]
Uterus	(22)	(25)
Atrophy		
Degeneration, Cystic		
Endometrium, Hyperplasia, Cystic	16 [1.8]	17 [1.9]
Vagina	(22)	(23)
Infiltration Cellular, Polymorphonuclear		2 [2.5]
HEMATOPOIETIC SYSTEM		
Bone Marrow	(22)	(24)
Fibrosis	\—- <i>,</i>	(-·)
Hyperplasia		3 [2.7]
Lymph Node	(1)	(4)
Lumbar, Hyperplasia, Lymphoid	( )	( )
Lumbar, Sinus, Dilatation		
Pancreatic, Hyperplasia, Lymphoid		
Renal, Angiectasis		
Renal, Hyperplasia, Lymphoid		
Renal, Thrombus		

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Time Report Requested: 12:30:59
First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
Lymph Node, Mandibular	(22)	(25)
Hyperplasia, Lymphoid	2 [1.0]	1 [2.0]
Lymph Node, Mesenteric	(21)	(24)
Angiectasis		
Hyperplasia, Lymphoid	2 [2.0]	3 [1.3]
Spleen	(22)	(25)
Hematopoietic Cell Proliferation	8 [2.0]	7 [2.6]
Hyperplasia, Lymphoid	16 [2.6]	16 [2.5]
Thymus	(21)	(24)
Atrophy		
Hyperplasia, Lymphoid	2 [2.5]	5 [2.2]
INTEGUMENTARY SYSTEM		
Mammary Gland	(22)	(25)
Skin	(22)	(25)
Inflammation, Suppurative	(22)	(20)
Ulcer		
MUSCULOSKELETAL SYSTEM		
Bone	(1)	(0)
Bone, Femur	(22)	(25)
Fibro-Osseous Lesion	(/	(20)
Skeletal Muscle	(0)	(0)
Degeneration	(0)	(0)
Degeneration		
NERVOUS SYSTEM		
Brain, Brain Stem	(21)	(25)
Brain, Cerebellum	(21)	(25)
Hemorrhage	( <del>-</del> · /	(-3)
Brain, Cerebrum	(21)	(25)
Mineralization	2 [1.0]	(23)
······································	2 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

Time Report Requested: 12:30:59 CAS Number: AZT3TCCOMBO First Dose M/F: NA / 12/22/06

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
Peripheral Nerve Axon, Degeneration	(0)	(0)
RESPIRATORY SYSTEM		
Lung	(22)	(25)
Hemorrhage Infiltration Cellular, Lymphocyte		3 [1.7]
Inflammation, Chronic Active Metaplasia, Osseous		
Nose	(22)	(25)
Hyaline Droplet	1 [1.0]	6 [1.8]
Trachea	(21)	(25)
SPECIAL SENSES SYSTEM		
Eye	(21)	(23)
Cataract		1 [1.0]
Harderian Gland	(22)	(24)
Infiltration Cellular, Lymphocyte		
Inflammation, Chronic Active		
URINARY SYSTEM		
Kidney	(22)	(25)
Casts Protein	9 [1.0]	15 [1.2]
Hydronephrosis		3 [3.0]
Infarct		-
Infiltration Cellular, Lymphocyte	7 [1.0]	11 [1.2]
Metaplasia, Osseous		1 [2.0]
Mineralization		
Renal Tubule, Regeneration	45-51	45-1
Urinary Bladder	(22)	(25)
Infiltration Cellular, Lymphocyte	5 [1.0]	3 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/04/2010 AVERAGE SEVERITY GRADES[b]

AZT+3TC combination

CAS Number: AZT3TCCOMBO

First Dose M/F: NA / 12/22/06

Time Report Requested: 12:30:59

Lab: NCTR

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

\*\*\* END OF REPORT \*\*\*